Amgen Adds $300M to Puerto Rico Budget; Novartis to Exit Oral Drug Factory in Germany

Why It Matters

Amgen’s injection of capital bolsters U.S. drug‑manufacturing resilience, while Novartis’s exit underscores a broader reshoring trend that could reshape global supply chains.

Key Takeaways

• Amgen adds $300M to Puerto Rico, targeting biologics capacity expansion
• Total U.S. investment by Amgen approaches $2B in the last 12 months
• Novartis will close its German oral‑drug plant, shifting production elsewhere
• FDA’s one‑day inspection pilot aims to speed approvals without compromising safety
• BioMADE’s ecosystem supports rapid biotech growth across U.S. regions

Pulse Analysis

Amgen’s latest $300 million injection into Puerto Rico reflects a deliberate strategy to diversify U.S. biomanufacturing away from traditional hubs on the mainland. The island offers tax incentives, a skilled workforce, and proximity to the U.S. market, making it an attractive site for scaling biologics output. By bolstering capacity there, Amgen not only safeguards its supply chain against geopolitical disruptions but also positions itself to meet rising demand for advanced therapies, potentially creating hundreds of high‑paying jobs.

Novartis’s decision to exit its oral‑drug factory in Germany illustrates a growing trend among multinational pharma firms to re‑evaluate European footprints amid cost pressures and regulatory complexities. The closure will likely affect several thousand employees and may trigger a transfer of production to lower‑cost regions or to newer, more automated sites. Analysts view this as part of a broader reshoring wave, where companies prioritize proximity to key markets and flexible manufacturing platforms over legacy facilities.

The backdrop of these strategic moves includes the FDA’s experimental one‑day inspection program, designed to accelerate product approvals while maintaining rigorous safety standards. Coupled with initiatives like BioMADE, which fosters collaborative biotech clusters across the United States, the regulatory environment is becoming more conducive to rapid innovation and localized production. Together, these forces are reshaping the pharmaceutical landscape, encouraging firms to invest where incentives, talent, and streamlined oversight converge.